BRPI0908049A2 - Uso de derivados de pririmidina para o tratamento de doenças dependentes de egfr ou de doenças que possuem resistência adquirida a agentes que são direcionados aos membros da família de egfr - Google Patents

Uso de derivados de pririmidina para o tratamento de doenças dependentes de egfr ou de doenças que possuem resistência adquirida a agentes que são direcionados aos membros da família de egfr

Info

Publication number
BRPI0908049A2
BRPI0908049A2 BRPI0908049-0A BRPI0908049A BRPI0908049A2 BR PI0908049 A2 BRPI0908049 A2 BR PI0908049A2 BR PI0908049 A BRPI0908049 A BR PI0908049A BR PI0908049 A2 BRPI0908049 A2 BR PI0908049A2
Authority
BR
Brazil
Prior art keywords
diseases
egfr
pririmidine
derivatives
agents
Prior art date
Application number
BRPI0908049-0A
Other languages
English (en)
Inventor
Carlos Garcia-Echeverria
Sauveur-Michel Maira
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0908049A2 publication Critical patent/BRPI0908049A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0908049-0A 2008-03-05 2009-03-04 Uso de derivados de pririmidina para o tratamento de doenças dependentes de egfr ou de doenças que possuem resistência adquirida a agentes que são direcionados aos membros da família de egfr BRPI0908049A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08152326 2008-03-05
PCT/EP2009/052564 WO2009109605A1 (en) 2008-03-05 2009-03-04 Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members

Publications (1)

Publication Number Publication Date
BRPI0908049A2 true BRPI0908049A2 (pt) 2015-08-11

Family

ID=39343633

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908049-0A BRPI0908049A2 (pt) 2008-03-05 2009-03-04 Uso de derivados de pririmidina para o tratamento de doenças dependentes de egfr ou de doenças que possuem resistência adquirida a agentes que são direcionados aos membros da família de egfr

Country Status (14)

Country Link
US (2) US20110033453A1 (pt)
EP (3) EP2259800B1 (pt)
JP (2) JP2011513364A (pt)
KR (1) KR20100131446A (pt)
CN (2) CN105343102A (pt)
AU (1) AU2009221164B2 (pt)
BR (1) BRPI0908049A2 (pt)
CA (1) CA2716518A1 (pt)
ES (1) ES2471452T3 (pt)
MX (1) MX2010009743A (pt)
PL (1) PL2259800T3 (pt)
PT (1) PT2259800E (pt)
RU (2) RU2496500C2 (pt)
WO (1) WO2009109605A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009013305A1 (en) * 2007-07-24 2009-01-29 Novartis Ag Use of imidazoquinolines for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members
JP2011523646A (ja) 2008-05-21 2011-08-18 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのリン誘導体
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
KR20130139999A (ko) * 2010-10-14 2013-12-23 어리어드 파마슈티칼스, 인코포레이티드 Egfr-유도된 암의 세포 증식을 억제하는 방법
AU2012250517B2 (en) 2011-05-04 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
MX342326B (es) 2011-09-27 2016-09-26 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
CN102397544A (zh) * 2011-11-25 2012-04-04 百泰生物药业有限公司 一种单克隆抗体用于治疗非小细胞肺癌的用途
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
CA2879704A1 (en) * 2012-08-16 2014-02-20 Novartis Ag Combination of pi3k inhibitor and c-met inhibitor
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
CA2903979A1 (en) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
EP3229803B1 (en) 2014-12-12 2020-01-29 Massachusetts General Hospital Treatment of breast cancer brain metastases
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
CN111529530B (zh) * 2020-04-02 2021-06-04 中山大学 一种吡啶并咪唑类STAT3抑制剂在制备延缓或逆转TKIs获得性耐药药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
EE200100603A (et) * 1999-05-14 2003-02-17 Imclone Systems Incorporated Inimese refraktaarsete kasvajate ravi epidermaalse kasvufaktori retseptori antagonistidega
DK2316831T3 (da) * 2002-11-21 2013-06-10 Novartis Ag 2-(Morpholin-4-yl)pyrimidiner som phosphotidylinositol (PI)-3-kinaseinhibitorer samt deres anvendelse ved behandling af cancer
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2009013305A1 (en) * 2007-07-24 2009-01-29 Novartis Ag Use of imidazoquinolines for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members

Also Published As

Publication number Publication date
EP2259800A1 (en) 2010-12-15
EP2259800B1 (en) 2014-05-07
JP5778735B2 (ja) 2015-09-16
JP2011513364A (ja) 2011-04-28
MX2010009743A (es) 2010-09-28
RU2013132018A (ru) 2015-01-20
KR20100131446A (ko) 2010-12-15
CN105343102A (zh) 2016-02-24
US20140161722A1 (en) 2014-06-12
WO2009109605A1 (en) 2009-09-11
JP2014040446A (ja) 2014-03-06
US20110033453A1 (en) 2011-02-10
AU2009221164A1 (en) 2009-09-11
ES2471452T3 (es) 2014-06-26
RU2010140435A (ru) 2012-04-10
PT2259800E (pt) 2014-08-06
RU2496500C2 (ru) 2013-10-27
AU2009221164B2 (en) 2012-07-26
CA2716518A1 (en) 2009-09-11
CN101959533A (zh) 2011-01-26
EP2591805A1 (en) 2013-05-15
EP2599499A1 (en) 2013-06-05
PL2259800T3 (pl) 2014-09-30

Similar Documents

Publication Publication Date Title
BRPI0814346A2 (pt) Uso de imidazoquinolinas para o tratamento de doenças dependentes de egfr ou doenças que adquiriram resistência a agentes que são direcionados aos membros da família de egfr.
HUE039731T2 (hu) l,3-difenilprop-2-én-l-on-származékok alkalmazása májbetegségek kezelésére
SMT201500206B (it) Composti spiro-ossindolici e loro uso come agenti terapeutici
HUE054495T2 (hu) Rák kezelésére szolgáló készítmény
BRPI0917013A2 (pt) métodos para tratar doenças alérgicas e outras condições inflamatórias, e para tratar ou prevenir doença, composto, composição farmacêutica, e, uso de um composto
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
BRPI0917138A2 (pt) composto, métodos para tratar doenças alérgicas e outras condições inflamatórias, rinite alérgica, e para tratar ou prevenir doença, composição farmacêutica, uso de um composto, e, combinação.
BRPI0716844A2 (pt) Inidores de quinase úteis para o tratamento de doenças proliferativas
DK2300609T3 (da) Hidtil ukendt flagellinbaserede immunadjuvansforbindelser samt anvendelse deraf
BRPI0807487A2 (pt) Uso de antagonistas de il-23 para o tratamento de infecção
PT3812360T (pt) Compostos de monoclorotrifluoropropeno e composições e métodos utilizando os mesmos
PT2376533T (pt) Formulação de anticorpos
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
CR11019A (es) 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas
BRPI0823082A2 (pt) Uso derivados de sesquiterpeno
BRPI0719210A2 (pt) Uso de compostos espiro-oxindol como agentes terapêuticos
BRPI0820568A2 (pt) Composto, composição farmacêutica, uso de um composto ou uma composição farmacêutica, e, método de tratamento de um humano ou animal
BRPI0809346A2 (pt) Compostos derivados substituídos de imidazopiridina e composição farmacêutica contendo os mesmos
BRPI0910557A2 (pt) composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e uso.
BRPI0911577A2 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
BRPI0917661A2 (pt) produto que contém macitentan, composição farmacêutica que o contém e uso de macitentan
BRPI0915439A2 (pt) composição tópica para o tratamento de ceratose actínica
HRP20150052T1 (xx) Fungicidni pripravak i postupak za suzbijanje bolesti biljaka
ECSP088745A (es) Derivados sustituidos de cromanol y su uso
BRPI0916571A2 (pt) composto derivado de alquilaminometiloxazolidinona tricíclo, medicamento e composição farmacêutica que o contém e uso do composto

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]